利伐沙班治疗非瓣膜性心房颤动有效性及安全性荟萃分析

Validity and safety of rivaroxaban in treating non-valvular atrial fibrillation:a meta-analysis

目的系统分析利伐沙班与华法林治疗非瓣膜性心房颤动(NVAF)患者的有效性及安全性。方法计算机检索中国科技期刊全文数据库、万方数据库,纳入符合入选标准的文献进行统计分析。结果共纳入5篇文献,结果显示利伐沙班与华法林治疗有效率无明显差异(OR=0.80,95%CI 0.4~1.6),出血风险明显降低(OR=0.54,95%CI 0.31~0.91)。结论利伐沙班与华法林治疗NVAF患者相比较,其预防栓塞有效性相当,出血发生风险降低。利伐沙班是安全、有效的药物,具有广阔的临床应用前景。

Objective A meta-analysis of published papers regarding this subject was conducted in the present study,aims to estimate the validity and safety of rivaroxaban and warfarin in non-valvular atrial fibrillation（NVAF）.Methods Pubmed database was searched up to August,2015 to identify eligible studies.Pooled odds ratio（OR） estimates and 95% confidence intervals（CIs） were calculated.Results Hemorrhage risk of rivaroxaban was less than warfarin（OR = 0.54,95% CI 0.31 ~ 0.91）,while embolism risk equally（OR = 0.80,95% CI 0.4 ~ 1.6）.Conclusion Rivaroxaban was safer than warfarin for the treatment of NVAF patients.